- UCLA scientists help author major report to accelerate cancer research and care, delivering on US Cancer Moonshot initiative
A fundamental shift in how cancer research is conducted and cancer care is provided in the United States is required in order to deliver on the US Cancer Moonshot initiative, according to a major new report published today in The Lancet Oncology.
November 01, 2017 9:30 AMdetail
- Renowned UCLA physician-scientist awarded collaborative grant to develop innovative technologies to detect and prevent lung cancer
UCLA cancer researcher Dr. Steven Dubinett will co-lead a $5 million collaborative grant from Stand Up to Cancer to develop new tools to diagnose lung cancer and protect against recurrence in people successfully treated for the disease.
October 26, 2017 2:30 PMdetail
- With $3M grant from Stand Up to Cancer, UCLA researcher to advance understanding of how a promising new combination therapy could overcome melanoma resistance to immunotherapy
Dr. Antoni Ribas, director of the UCLA Jonsson Comprehensive Cancer Center’s Tumor Immunology Program and a professor of medicine at the David Geffen School of Medicine, has received a $3 million grant from Stand Up to Cancer to study the factors that shape how metastatic melanoma responds to a promising new drug combination therapy.
October 13, 2017 9:45 AMdetail
- UCLA scientist honored for outstanding contributions to advancing the understanding of the molecular mechanisms of cancer
Dr. Guillaume Chanfreau, a professor of chemistry and biochemistry at the David Geffen School of Medicine, will receive the American Cancer Society’s Giants of Science Determination Award for his outstanding contributions to the study of the molecular mechanisms that drive cancer.
October 13, 2017 9:45 AMdetail
- Make cancer less scary
This Halloween, researchers at the UCLA Jonsson Comprehensive Cancer Center share what scares them the most and remind us how important philanthropy is to fueling the research and support services so vital to cancer patients and their families.
October 13, 2017 9:00 AMdetail
- When undergoing cancer therapy, a patient’s sense of taste may change
Both cancer and cancer treatments can have unexpected side effects for patients. One of the surprising ones, for some patients, is that the taste of certain foods may begin to change.
October 10, 2017 10:00 AMdetail
- Combination treatment targeting glucose in advanced brain cancer shows promising results in preclinical study
UCLA scientists have discovered a potential combination treatment for glioblastoma, the deadliest form of brain cancer in adults.
October 09, 2017 9:00 AMdetail
- Renowned UCLA scientist to receive prestigious honor for advancing our understanding of how to combat the complexity of cancer
Dr. Thomas Graeber, a professor of molecular and medical pharmacology and director of the UCLA Metabolomics Center, has received the American Cancer Society’s Giants of Science Passion Award for his outstanding contributions to study of the mechanisms that make cancer cells sensitive or resistant to therapies.
October 05, 2017 11:00 AMdetail
- UCLA researcher receives $1M grant for prostate cancer research
A researcher from UCLA’s Jonsson Comprehensive Cancer Center will receive a $1 million grant over the next two years to fund research that profiles molecular changes that occur in prostate cancers associated with metastatic progression and treatment resistance.
October 05, 2017 8:00 AMdetail
- UCLA researchers awarded $1M grant to advance prostate cancer research
UCLA researchers Drs. Johannes Czernin and Caius Radu have been awarded a 2017 Challenge Award from the Prostate Cancer Foundation to fund their preclinical studies and clinical trials testing, a novel radiation-emitting targeted therapy for prostate cancer.
October 05, 2017 6:00 AMdetail
- New method to measure cell stiffness could lead to improved cancer treatments
UCLA biophysicists have developed a new method to rapidly determine a single cell’s stiffness and size — which could ultimately lead to improved treatments for cancer and other diseases.
October 03, 2017 10:00 AMdetail
- After clinical testing at UCLA, immunotherapy drug approved by FDA to treat stomach cancer
Pembrolizumab, a drug that has effectively extended the lives of countless people with many types of cancer, has now been approved by the U.S. Food & Drug Administration to treat people with metastatic gastric adenocarcinoma, the most common form of stomach cancer.
October 03, 2017 6:00 AMdetail
- UCLA early career scientist receives prestigious recognition
A researcher from UCLA’s Jonsson Comprehensive Cancer Center will receive a two-year $100,000 grant by the American Society for Radiation Oncology (ASTRO). The junior faculty career research-training award is only given to one junior faculty physician-scientist a year. The funding gives early career physicians and researchers the opportunity to develop careers and focus on research relevant to radiation oncology, biology or physics.
September 25, 2017 8:00 AMdetail
- UCLA researcher honored with special recognition by LA City Council
On Sept. 19, 2017, Dr. Sanaz Memarzadeh, director of the UCLA G.O. Discovery Lab: Gynecologic Oncology Cancer Research Lab and UCLA Jonsson Comprehensive Cancer Center member, was honored for her commitment to ovarian cancer research by the City of Los Angeles. Memarzadeh and the Jonsson Cancer Center were both presented with special recognition during the event, held at Los Angeles City Hall, by council member Paul Koretz.
September 19, 2017 12:00 PMdetail
- UCLA brain cancer program designated a specialized program of research excellence by the National Cancer Institute
The brain cancer program at UCLA's Jonsson Comprehensive Cancer Center and the UCLA Brain Tumor Center has been designated a Specialized Program of Research Excellence, or SPORE by the National Cancer Institute, making it one of only five brain cancer programs nationwide to receive this national recognition and substantial research funding.
September 19, 2017 10:00 AMdetail
- Treatment-resistant melanoma may be vulnerable to a drug holiday, UCLA study finds
A UCLA study has uncovered the mechanisms by which treatment-resistant melanoma become vulnerable to cessation of a class of drugs called MAP kinase (MAPK)-targeted inhibitors. By identifying these mechanisms, the scientists discovered that therapeutic benefits for patients could derive from a one-two punch of cessation of MAPK inhibitors followed by a class of drugs called DNA repair inhibitors.
September 18, 2017 12:00 PMdetail
- UCLA receives $650,000 gift from Avon to fund breast cancer program
Avon Cares for Life, a program of UCLA’s Jonsson Comprehensive Cancer Center dedicated to enhancing the quality of care for uninsured and underinsured patients who have been diagnosed with or are at risk for breast cancer, has received a $650,000 donation from Avon Breast Cancer Crusade.
September 12, 2017 10:00 AMdetail
- University of California Cancer Consortium takes on California’s $14 billion killer
The University of California’s five academic cancer centers, home to some of the world’s leading scientists and physicians, have formed a consortium to better address California’s most pressing cancer-related problems and opportunities, UC President Janet Napolitano and Dr. John Stobo, executive vice president of UC Health, announced today.
September 11, 2017 10:00 AMdetail
- UCLA opens first engineered blood stem cell clinical trial for cancers with the NY-ESO-1 tumor marker
UCLA scientists have initiated a phase 1 clinical trial to test a novel cancer treatment for certain kinds of cancers that have a specific tumor marker called NY-ESO-1. Directed by Dr. Antoni Ribas, the trial is the first to genetically engineer blood-forming stem cells to produce cancer-fighting white blood cells called T cells, which constitute part of the immune system.
September 11, 2017 9:00 AMdetail
- Study unlocks how changes in gene activity early during therapy can establish the roots of drug-resistant melanoma
A UCLA-led study of changes in gene activity in BRAF-mutated melanoma suggests these epigenomic alterations are not random but can explain how tumors are already developing resistance as they shrink in response to treatment with a powerful class of drugs called MAP kinase (MAPK)-targeted inhibitors.
September 08, 2017 9:00 AMdetail